image credit- shutterstock
Kyowa Kirin, a Japan-based global specialty pharmaceutical company, has announced the termination of the current rocatinlimab development and commercialisation collaboration with Amgen.
Kyowa Kirin will control the global rocatinlimab programme, including regulatory filings and future commercialisation. This business decision is the result of a strategic portfolio prioritization by Amgen.
The companies are initiating a smooth and orderly transition of the programme, with a focus on ensuring continuity for participants currently enrolled in clinical trial programmes. Amgen, who has partnered with Kyowa Kirin on numerous investigational therapies over 41 years, will continue to manufacture rocatinlimab.
Rocatinlimab was discovered and advanced by Kyowa Kirin, drawing on the company’s deep expertise in immunology and antibody engineering. It reflects the strength of the company’s internal R&D capabilities and long-term investment in science that targets the underlying drivers of chronic inflammatory disease, not just its symptoms.
The Phase 3 ROCKET programme is a comprehensive clinical development programme in atopic dermatitis, which consists of eight pivotal studies, evaluating both long-term efficacy and safety. The programme includes diverse patient populations, including adults and adolescents, systemic treatment– naïve patients, as well as those previously treated with biologics and JAK inhibitors, underscoring its potential as a meaningful treatment option for people living with atopic dermatitis across a broad range of clinical scenarios.
